Targeted & controlled bone healing

The core business of Kuros Biosciences is to develop and commercialize innovative orthobiological products for tissue repair and regeneration. The Company’s strategy is to license non-core assets with specialized partners and, if successful, to participate from their medical and commercial development in the form of milestone payments and royalties.

CYT003 and VLP platform

Checkmate Pharmaceuticals LLC (www.checkmatepharma.com)

In August 2015, Kuros exclusively licensed its clinically validated product candidate  CYT003, the virus-like particle (VLP) platform, and other technologies related to oligonucleotide synthesis, Checkmate Pharmaceuticals LLC for development in oncology. Kuros may receive up to USD 90 million in development milestones and may receive up to double-digit royalties on net sales from successfully developed products. In April 2017, Checkmate paid Kuros a first milestone of USD 1 million upon dosing of the first melanoma patient in its Phase 1b clinical trial.

In early January 2018, Kuros and Checkmate extended their existing agreement from oncology to all indications and a broad range of product candidates. Under the amendment of the license, Kuros received an upfront payment and is eligible for additional milestone payments and royalties for successfully developed products.

Pfizer (www.pfizer.com)

Pfizer is developing a novel anti-IgE vaccine based on Cytos' Qb VLP platform under an exclusive commercial license agreement with Cytos. A Phase 1 clinical trial with the anti-IgE vaccine began in 2013 and was completed in June 2015.

Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 44 733 47 47   Fax: +41 44 733 47 40   Email: info@kurosbio.com

About Kuros

  1. Overview
  2. Executive Committee
  3. Board
  4. Careers

Products

  1. MagnetOs

Pipeline

  1. Pipeline
  2. Spinal fusion
    KUR-113
  3. Fracture repair
    KUR-111
    KUR-113
  4. Surgical Sealants
    Neuroseal (KUR-023)

Technologies

  1. Surface Science Technology
  2. Fibrin-Based
  3. Synthetic Cross-Linking Technology
  4. Immune Modulation

Partnerships

  1. Collaborations
  2. Business Development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & Presentations
  4. Analysts
  5. Calendar
  6. Corporate governance
  7. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Collaborations

The core business of Kuros Biosciences is to develop and commercialize innovative orthobiological products for tissue repair and regeneration. The Company’s strategy is to license non-core assets with specialized partners and, if successful, to participate from their medical and commercial development in the form of milestone payments and royalties.

CYT003 and VLP platform

Checkmate Pharmaceuticals LLC (www.checkmatepharma.com)

In August 2015, Kuros exclusively licensed its clinically validated product candidate  CYT003, the virus-like particle (VLP) platform, and other technologies related to oligonucleotide synthesis, Checkmate Pharmaceuticals LLC for development in oncology. Kuros may receive up to USD 90 million in development milestones and may receive up to double-digit royalties on net sales from successfully developed products. In April 2017, Checkmate paid Kuros a first milestone of USD 1 million upon dosing of the first melanoma patient in its Phase 1b clinical trial.

In early January 2018, Kuros and Checkmate extended their existing agreement from oncology to all indications and a broad range of product candidates. Under the amendment of the license, Kuros received an upfront payment and is eligible for additional milestone payments and royalties for successfully developed products.

Pfizer (www.pfizer.com)

Pfizer is developing a novel anti-IgE vaccine based on Cytos' Qb VLP platform under an exclusive commercial license agreement with Cytos. A Phase 1 clinical trial with the anti-IgE vaccine began in 2013 and was completed in June 2015.